CompletedNot Applicable

Methylprednisolone for Children With Severe Mycoplasma Pneumoniae Pneumonia (MCMP)

China424 participantsStarted 2014-12

Plain-language summary

The study is designed to investigate difference in percentage of presentation of atelectasis, bronchiectasis, bronchiolitis obliterans, or consolidation in 6 months after discharge in those treated with a low dose regimen of methylprednisolone initiated with 2 or 4 mg/kg/d for 3 days followed by tapering, combined with sequential treatment with azithromycin versus a high dose regimen of methylprednisolone initiated with 10 mg/kg/d for 3 days followed by tapering, combined with sequential treatment with azithromycin.

Who can participate

Age range29 Days – 17 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Less than 18 years old
✓. Severe pneumonia that is defined as pneumonia with one of the followings:
✓. Serum M. pneumoniae antibody≥ 1:320, or serum M. pneumoniae antibody≥ 1:160 with positive PCR of M. pneumoniae or seroconversion (increased antibody titers ≥4 folds) Subject/Guardian is informed and consent.

What they're measuring

pulmonary lesions

Timeframe: 6 months

Trial details

NCT IDNCT02303587

SponsorBeijing Children's Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-10-16

View on ClinicalTrials.gov More Mycoplasma Pneumoniae Pneumonia trials